332 related articles for article (PubMed ID: 31485637)
1. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.
Duan X; Liu J; Cui J; Ma B; Zhou Q; Yang X; Lu Z; Du Y; Su C
Mol Med Rep; 2019 Oct; 20(4):3773-3781. PubMed ID: 31485637
[TBL] [Abstract][Full Text] [Related]
2. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
[TBL] [Abstract][Full Text] [Related]
3. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of TIGIT but not neuropilin-1 in patients with type 2 diabetes mellitus.
Hoseini-Aghdam M; Sheikh V; Eftekharian MM; Rezaeepoor M; Behzad M
Immunol Lett; 2020 Sep; 225():1-8. PubMed ID: 32540486
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
6. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
Fuhrman CA; Yeh WI; Seay HR; Saikumar Lakshmi P; Chopra G; Zhang L; Perry DJ; McClymont SA; Yadav M; Lopez MC; Baker HV; Zhang Y; Li Y; Whitley M; von Schack D; Atkinson MA; Bluestone JA; Brusko TM
J Immunol; 2015 Jul; 195(1):145-55. PubMed ID: 25994968
[TBL] [Abstract][Full Text] [Related]
7. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
Li S; Ding J; Wang Y; Wang X; Lv L
J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
[TBL] [Abstract][Full Text] [Related]
8. Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.
Sun H; Huang Q; Huang M; Wen H; Lin R; Zheng M; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Hepatology; 2019 Jul; 70(1):168-183. PubMed ID: 30411378
[TBL] [Abstract][Full Text] [Related]
9. PD-1
Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
[TBL] [Abstract][Full Text] [Related]
10. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
11. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
12. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
13. CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis.
Jin AL; Zhang CY; Zheng WJ; Xian JR; Yang WJ; Liu T; Chen W; Li T; Wang BL; Pan BS; Li Q; Cheng JW; Wang PX; Hu B; Zhou J; Fan J; Yang XR; Guo W
Clin Transl Med; 2022 Apr; 12(4):e794. PubMed ID: 35384345
[TBL] [Abstract][Full Text] [Related]
14. Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT.
Gilbert RM; Zhang X; Sampson RD; Ehrenstein MR; Nguyen DX; Chaudhry M; Mein C; Mahmud N; Galatowicz G; Tomkins-Netzer O; Calder VL; Lightman S
Front Immunol; 2018; 9():907. PubMed ID: 29774027
[TBL] [Abstract][Full Text] [Related]
15. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
Transl Oncol; 2024 Jul; 45():101961. PubMed ID: 38631259
[TBL] [Abstract][Full Text] [Related]
16. Loss of CD155 expression predicts poor prognosis in hepatocellular carcinoma.
Qu P; Huang X; Zhou X; Lü Z; Liu F; Shi Z; Lü L; Wu Y; Chen Y
Histopathology; 2015 Apr; 66(5):706-14. PubMed ID: 25320021
[TBL] [Abstract][Full Text] [Related]
17. TIGIT expression levels on CD4+ T cells are correlated with disease severity in patients with psoriasis.
Wang FF; Wang Y; Wang L; Wang TS; Bai YP
Clin Exp Dermatol; 2018 Aug; 43(6):675-682. PubMed ID: 29512851
[TBL] [Abstract][Full Text] [Related]
18. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
20. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma).
Sun Y; Luo J; Chen Y; Cui J; Lei Y; Cui Y; Jiang N; Jiang W; Chen L; Chen Y; Kuang Y; Tang K; Ke Z
Int Immunopharmacol; 2020 Mar; 80():106198. PubMed ID: 31954274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]